

ABSTRACT

European Patent No. 0 388 914

Date of Publication: 26 SEP 90

The invention relates to murine monoclonal antibodies (MAK) A, B, C and D and their binding to tumor associated antigens. The complete nucleotide sequences of the V-genes of these MAK are described, so that humanized chimeric MAK can be produced with a murine variable domain grafted to human hypervariable regions (Complementary Determining Regions = CDR). Such antibody constructs avoid the side effects of murine MAK when used in human therapies and in vivo diagnosis.